The 2020/1 Blended Learning Journey on Metastatic Renal Cell Carcinoma (mRCC) LIVE WEBINAR for APAC - Saturday, 24 April 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The 2020/1
Blended Learning Journey
on Metastatic Renal
Cell Carcinoma (mRCC)
LIVE WEBINAR for APAC
Saturday,
24 April 2021
from 11:00 to 12:00 CEST
OVERVIEW
Renal Cell Carcinoma (RCC) is a common tumor of the elderly, which has consistently
increased in incidence over the past decade. While operative techniques have
advanced in recent years and now offer renal preservation and minimal operative
trauma where possible, adjuvant measures are not established. Medical treatment
remains mostly confined to those with relapsed or metastatic disease, when local
therapies are not suitable. The first wave of medical treatments for RCC consisted of
cytokines, which had some impact on patient prognosis (overall survival increased
to a median of 13 months), but clearly lacked efficacy. Unraveling the molecular
carcinogenesis of clear cell RCC spurred the development of targeted therapies,
tyrosine kinase inhibitors (TKI), which inhibit the tumor vasculature and have
noticeably improved the efficacy of RCC medical treatment. More recently, check
point inhibitors (CPI) have entered the therapeutic arena - the latest milestone of
clinical development. These tools allow further optimization of treatment by permitting
combinations of different therapies. Today, first-line therapies are composed of CPI-
based combinations, which have shifted median overall survival expectation to >40
months. This live webinar brings together a panel of international experts, who will
discuss the rapid development of medical treatments with a particular focus on
contemporary medical treatment in advanced or metastatic RCC.
LEARNING OBJECTIVES
By attending this live educational webinar learners will be able to:
• Diagnose RCC and categorize the disease into stages
• Use the stages of disease to help inform therapy decisions
• Know the latest guideline recommendations for patients with RCC
• Understand the science/trials behind the latest guideline updates
• Be more confident about prescribing choices for patients at all stages of RCC
TARGET AUDIENCE
This webinar is designed for Oncologists, Urologists and specialists from the APAC
Region, involved in the diagnosis and management of patients with metastatic renal
cell carcinoma (mRCC).
LANGUAGE
The official language of this live educational webinar is English.
Simultaneous translation into Japanese will be provided.
CME ACCREDITATION
The 2020/1 Blended Learning Journey on Metastatic Renal Cell
Carcinoma (mRCC) - LIVE WEBINAR for APAC, 24/04/2021 - 24/04/2021
has been submitted for CME accreditation to the European Accreditation Council for
Continuing Medical Education (EACCME®).
2CME PROVIDER
Scientific Seminars International Foundation
CME Manager: Flaminia Masprone
T +39 380 1504116 - F +39 06 4827169
info@scientificseminars.com
PRE-REGISTRATION AND SURVEY
To access the live webinar, please register by clicking on the below link:
https://www.elearning.scientificseminars.com/the-2020-21-blended-
learning-journey-on-metastatic-renal-cell-carcinoma-mrcc/live-webinar-
for-apac/
and complete a very short survey covering your current knowledge of the subject
matter prior to attending the webinar.
3FACULTY
Viktor Grünwald Jens Bedke
Professor for interdisciplinary Department of Urology
genitourinary oncology Eberhard Karls University Tübingen
University Hospital Essen (AöR) Tübingen, Germany
West-German Cancer Center Essen
Clinic for Medical Oncology and
Clinic for Urology
Essen, Germany
Eto Masatoshi
Professor and Chairman
Department of Urology
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan
4SATURDAY, 24 APRIL 2021
from 11:00 to 12:00 CEST
11:00 Welcome and introduction
V. Grünwald (Germany)
11:05 L1 Background and drug development in mRCC
V. Grünwald (Germany)
11:15 L2 Current clinical data
Eto Masatoshi (Japan)
Abstract: The rapidly evolving treatment landscape of mRCC has led to the
latest development of check point inhibitor (CPI)-based drug combinations
in first line treatment. Although these combinations offer broad clinical
activity and their use is associated with a median overall survival >40
months, the next generation of CPI-based combinations appeared. These
later combinations combine CPIs with 3rd generation tyrosine kinase
inhibitors (TKI) to broaden the clinical activity. We will discuss the latest data
and their implication for the treatment landscape in mRCC. In details:
• Javelin-101 renal
• KN-426
• Checkmate 214
• Cheeckmate 9ER
• CLEAR
11:30 L3 Clinical case - Individualizing therapy for a treatment naïve
patient just diagnosed with mRCC: treatment options, and their
progress on therapy
J. Bedke (Germany)
Abstract: We will present a case scenario of a patient with mRCC, who
is rendered treatment-naïve. The interpretation of clinical data will be
discussed, waying pros and cons of different treatment options in order to
individualize therapeutic choices.
11:45 P Panel discussion
11:55 Summary and closing remarks
V. Grünwald (Germany)
12.00 End of the live webinar
LEGEND 5
L: Lecture; P: Panel discussionAll Scientific Seminars International Foundation programs are organized solely to promote the
exchange and dissemination of scientific and medical information. No forms of promotional
activities are permitted. There may be presentations discussing investigational uses of various
products. These views are the responsibility of the named speakers, and do not represent an
endorsement or recommendation on the part of Scientific Seminars International Foundation.
This independent educational program is made possible thanks to an educational grant
received from Merck Healthcare KGaA Darmstadt, Germany.
6Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com
Copyright © Scientific Seminars International Foundation, 2021. All rights reserved.
7You can also read
